Compare FTHM & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTHM | ACXP |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 6.2M |
| IPO Year | 2020 | 2021 |
| Metric | FTHM | ACXP |
|---|---|---|
| Price | $0.66 | $1.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $95.50 |
| AVG Volume (30 Days) | 89.1K | ★ 179.1K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $420,477,000.00 | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.40 | $1.31 |
| 52 Week High | $3.37 | $8.34 |
| Indicator | FTHM | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 47.60 |
| Support Level | $0.48 | $1.33 |
| Resistance Level | $0.71 | $1.75 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 42.48 | 37.50 |
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.